Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

NCT01025479 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 829

Last updated 2010-06-30

No results posted yet for this study

Summary

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Conditions

Sponsors & Collaborators

Principal Investigators

  • Joon Woo Bahn, MD · AstraZeneca Korea

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025479 on ClinicalTrials.gov